Last reviewed · How we verify
SEP-380135
At a glance
| Generic name | SEP-380135 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults (PHASE1)
- A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEP-380135 CI brief — competitive landscape report
- SEP-380135 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI